Ardsley Advisory Partners’s Adverum Biotechnologies ADVM Stock Holding History

Ardsley Advisory Partners’s Portfolio ADVM Stock Details ADVM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-11,000	Closed	-$666K	–	105
2018 Q3	$666K	Hold	11,000	–	–	0.09%	87
2018 Q2	$583K	Buy	11,000 +1,000	+10%	+$60.1K	0.09%	100
2018 Q1	$580K	Hold	10,000	–	–	0.09%	91
2017 Q4	$350K	Buy	+10,000	New	+$329K	0.04%	104

Other funds holding ADVM

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

WS Management Jacksonville, Florida $1.13B AUM 53.44% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Ardsley Advisory Partners's ADVM Position: Q4 2018 in Review

Ardsley Advisory Partners sold out of Adverum Biotechnologies (ADVM) in Q4 2018, closing a stake of 11,000 shares — an estimated $666K sold.

Ardsley Advisory Partners first reported a position in ADVM in Q4 2017 and held it in 4 quarters. The position peaked at $666K in Q3 2018. 86 funds tracked by Wall St. Rank hold ADVM as of Q4 2018.

Ardsley Advisory Partners reported no remaining Adverum Biotechnologies position as of Q4 2018 after selling out during the quarter.
Ardsley Advisory Partners sold 11,000 Adverum Biotechnologies shares in Q4 2018, an estimated $666K.
Ardsley Advisory Partners first reported a position in Adverum Biotechnologies in Q4 2017 and held it in 4 quarters.
Ardsley Advisory Partners's Adverum Biotechnologies position peaked at $666K in Q3 2018.
86 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q4 2018.

Based on Ardsley Advisory Partners's 13F filing for Q4 2018, filed 14 Feb 2019.